Cantor Fitzgerald Estimates TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Travere Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of $1.86 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share.

A number of other brokerages also recently issued reports on TVTX. JPMorgan Chase & Co. lifted their price target on Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Scotiabank reaffirmed an "outperform" rating on shares of Travere Therapeutics in a report on Friday, April 11th. Bank of America lifted their price target on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. HC Wainwright raised Travere Therapeutics to a "buy" rating and set a $30.00 price target for the company in a report on Wednesday. Finally, Stifel Nicolaus lifted their price target on Travere Therapeutics from $22.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $32.14.

Travere Therapeutics Stock Down 2.9%

TVTX traded down $0.44 on Wednesday, hitting $14.50. 1,582,706 shares of the company were exchanged, compared to its average volume of 1,618,486. Travere Therapeutics has a twelve month low of $6.80 and a twelve month high of $25.29. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -3.54 and a beta of 0.75. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The firm has a 50-day moving average price of $16.87 and a two-hundred day moving average price of $18.53.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The firm had revenue of $81.73 million during the quarter, compared to analysts' expectations of $77.44 million. During the same period in the previous year, the firm posted ($1.76) EPS. Travere Therapeutics's revenue for the quarter was up 83.3% on a year-over-year basis.

Insider Buying and Selling at Travere Therapeutics

In related news, insider Peter Heerma sold 1,771 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $37,279.55. Following the sale, the insider now owns 128,215 shares in the company, valued at $2,698,925.75. This represents a 1.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Eric M. Dube sold 18,924 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $398,350.20. Following the completion of the sale, the chief executive officer now owns 419,173 shares in the company, valued at approximately $8,823,591.65. This represents a 4.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,527 shares of company stock valued at $473,814 in the last ninety days. Insiders own 4.19% of the company's stock.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Entropy Technologies LP acquired a new stake in Travere Therapeutics during the 4th quarter valued at $214,000. US Bancorp DE lifted its stake in shares of Travere Therapeutics by 323.4% during the 4th quarter. US Bancorp DE now owns 31,795 shares of the company's stock worth $554,000 after purchasing an additional 24,286 shares during the period. Northern Trust Corp lifted its stake in shares of Travere Therapeutics by 11.3% during the 4th quarter. Northern Trust Corp now owns 754,395 shares of the company's stock worth $13,142,000 after purchasing an additional 76,358 shares during the period. Wellington Management Group LLP purchased a new position in shares of Travere Therapeutics during the 4th quarter worth $583,000. Finally, Swiss National Bank lifted its stake in shares of Travere Therapeutics by 12.8% during the 4th quarter. Swiss National Bank now owns 151,900 shares of the company's stock worth $2,646,000 after purchasing an additional 17,200 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.